NCT00446485

Efficacy and Safety of Ginkgo Biloba Extract in Mild Cognitive Impairment and Cerebrovascular Insufficiency

Efficacy and Safety of Ginkgo Biloba Standardized Extract (24% Ginkoflavonoglicozides and 6% Terpenes) in Treatment of Mild Cognitive and Concentration Impairment

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 90 (actual)
• Sponsor: Milsing d.o.o. · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to determine weather Ginkgo biloba standardized extract (24% ginkoflavonoglicozides and 6% terpenes) is effective in treatment of cognitive and concentration impairment

Detailed description

Inclusion criteria is cerebrovascular insufficiency MNSE\>20. 90 patients are divided into three groups randomly. First group is being administered 120 mg ginkgo biloba extract, second group 60 mg of the extract and the third group has being administered placebo during the period of 6 months. Methods used for evaluation are SCAG, MMSE, MDRS, VFT, CGI, TCD and color Doppler of carotid arteries. Methods used for follow up safety include: routine blood tests, biochemical tests, neurologic and physical examination, vital signs and ECG.

Conditions

• Mild Cognitive Impairment
• Cerebrovascular Insufficiency

Interventions

Type	Name	Description
DRUG	Ginkgo biloba standardized extract 24/6	tablets, 120 mg/day (60 mg two times daily) during 6 months
DRUG	Ginkgo Biloba standardized extract 24/6	tablets, 60 mg/day during 6 months
DRUG	placebo	placebo during 6 months

Timeline

• Start date: 2007-05-01
• Primary completion: 2010-04-01
• Completion: 2010-04-01
• First posted: 2007-03-13
• Last updated: 2015-09-28

Locations

1 site across 1 country: Croatia